Docket No.: HO-P.03167US0

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Kenji Sato et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently

Art Unit: N/A

For:

Proteoglycan Isolated From Cartilaginous Fish

and Process for Producing the same

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed concurrently with the filing of the U.S. filing National Phase Application.

A summary/abstract translation of the non-English language references is enclosed.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other 25594574

Application No.: Not Yet Assigned

Docket No.: HO-P03167US0

IAP20 Rec'd PCT/PTO 03 APR 2006

material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P03167US0.

Dated: April 3, 2006

Respectfully submitted,

Allen E. White

Registration No.: 55,727

FULBRIGHT & JAWORSKI L.L.P.

Fulbright Tower

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Attorney for Applicant

## IAP20 Rec'd FCTIPTO 03 APR 2006.

PTO/SB/08A (10-01) Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Sut   | estitute for form 1449A/PTO |         |            | Complete if Known      |                        |  |
|-------|-----------------------------|---------|------------|------------------------|------------------------|--|
|       |                             |         |            | Application Number     | NotivetiAssigned4 4 00 |  |
| 11    | <b>VFORMATION</b>           | V DI    | SCLOSURE   | Filing Date            | Concurrently           |  |
| S     | STATEMENT I                 | BY A    | APPLICANT  | First Named Inventor   | Kenji Sato             |  |
|       |                             |         |            | Art Unit               | N/A                    |  |
|       | (use as many sh             | eets as | necessary) | Examiner Name          | Not Yet Assigned       |  |
| Sheet | 1                           | of      | 2          | Attorney Docket Number | HO-P03167US0           |  |

|                       | U.S. PATENT DOCUMENTS |   |                                |   |  |  |  |  |
|-----------------------|-----------------------|---|--------------------------------|---|--|--|--|--|
| Examiner<br>Initials* | Cite<br>No.1          | Document Number  Number-Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |  |  |  |
|                       | AA                    | US-4,473,551  | 09-25-1984                     | Schinitsky                                      |  |  |  |  |
|                       | AB                    | US-6,379,709  | 04-30-2002                     | Slim et al.                                     |  |  |  |  |

|           |              | FOREI   | GN PATENT        | DOCUMENTS                   |  |  |
|-----------|--------------|---|------------------|-----------------------------|--|--|
| Examiner  | Cite<br>No.1 | Foreign Patent Document   | Publication Date | Name of Patentee or         | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |  |
| Initials* |              | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) | MM-DD-YYYY       | Applicant of Cited Document |  |  |
|           | BA           | JP-9-512563   | 12-16-1997       | Dupont et al.               |  |  |
|           | BB           | JP-2001-48795   | 02-20-2001       | Yagita                      |  |  |
|           | вс           | JP-2003-246742  | 02-09-2003       | Dupont et al.               |  |  |
|           | BD           | JP-2003-300858  | 10-21-2003       | Osumi et al.                |  |  |
|           | BE           | WO-95/32722   | 12-07-1995       | Dupont et al.               |  |  |
|           | BF           | WO-96/23512   | 08-08-1996       | Dupont et al.               |  |  |
|           | BG           | WO-03/068249  | 08-21-2003       | Kralovec et al.             |  |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

|                      |  | NON PATENT LITERATURE DOCUMENTS  |  |  |  |  |
|----------------------|--|--|--|--|--|--|
| Examiner<br>Initials | Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. |  |  |  |  |  |
|                      | CA   | Davis et al., "Inhibitiion of Angiogenesis by Oral Ingestion of Powdered Shark Cartilage in a Rat Model," <i>Microvascular Research</i> , 54: 178-182, 1997.   |  |  |  |  |
|                      | СВ   | Ernst, "Shark cartilage for cancer?" The Lancet, 351: 298, 1998.   |  |  |  |  |
|                      | CC   | Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Medicine</i> , 1: 27-31, 1995.  |  |  |  |  |
|                      | CD   | Gingras et al., "Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills?" Cancer and Metastasis Reviews, 19: 83-86, 2000.   |  |  |  |  |
|                      | CE   | lki et al., "Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with <i>N</i> -nitrosobis(2-oxopropyl)amine," <i>Carcinogenesis</i> , 20(7): 1323-1329, 1999. |  |  |  |  |
|                      | CF   | Kitahashi et al., "Changes in Serum Matrix Metalloproteinase(MMPs) and Serine Protease Levels and Inhibition of Their Activity in Hamsters Fed with Shark Cartilage Extracts," Annual Meeting of Japan Society Bioscience, Biotechnology, and Agrochemistry, 2003 (abstract in English).                       |  |  |  |  |
|                      | CG   | Lee et al., "Shark Cartilage Contains Inhibitors of Tumor Angiogenesis," <i>Science</i> , 221: 1185-1187, 1983.  |  |  |  |  |
|                      | СН   | Moses et al, "A Metalloproteinase Inhibitor as an Inhibitor of Neovascularization," J. Cell. Biochem., 47: 230-235, 1991.  |  |  |  |  |
|                      | СІ   | Murata, "Effects of Bovine and Shark Cartilage Water Extracts on Pancreatic Ductal Carcinogenesis in Hamsters," Journal of Nara Medical Association, 53(5-6): 241-252, 2002 (with English translation).  |  |  |  |  |

| Examiner  | Date       |  |
|-----------|------------|--|
| Signature | Considered |  |
|           |            |  |

25594576

## JAP20 Rec'd PCT/PTO 03 APR 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449A/PTO     |           |        |          | Complete if Known      |                     |  |
|-----------------------------------|-----------|--------|----------|------------------------|---------------------|--|
|                                   |           |        |          | Application Number     | Not Yet Assigned OO |  |
| 11                                | NFORMATIC | ON DIS | CLOSURE  | Filing Date            | oncurrently         |  |
| S                                 | TATEMENT  | BY A   | PPLICANT | First Named Inventor   | Kenji Sato          |  |
| (use as many sheets as necessary) |           |        |          | Art Unit               | N/A                 |  |
|                                   |           |        |          | Examiner Name          | Not Yet Assigned    |  |
| Sheet                             | 2         | of     | 2        | Attorney Docket Number | HO-P03167US0        |  |

| CJ | Naito et al., "Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase |  |
|----|--|--|
|    | Inhibitor," Int. J. Cancer, 58: 730-735, 1994.   |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

|           |            | <br> |
|-----------|------------|------|
| Examiner  | Date       |      |
| Signature | Considered |      |
|           |            |      |

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.